Vector Pharma FZCO Announce Exclusive Distribution Agreement with Ascendis Pharma A/S for Skytrofa (lonapegsomatropin) and Yorvipath (palopegteriparatide) in Gulf Cooperation Council Countries

Vector Pharma FZCO (Vector) today announced that it has entered into an exclusive distribution agreement with Danish company Ascendis Pharma A/S (Nasdaq: ASND) to commercialize both Skytrofa™ and Yorvipath™ in the Gulf Cooperation Council (GCC) countries of Saudi Arabia, United Arab Emirates, Kuwait, Oman, Qatar and Bahrain.

Under the terms of this exclusive distribution agreement, Vector will employ its sales and marketing expertise to distribute both Skytrofa and Yorvipath to patients in the GCC countries for the treatment of pediatric growth hormone deficiency (GHD) in the case of Skytrofa, and adult hypoparathyroidism in the case of Yorvipath.

“I am excited to announce this regional agreement with Ascendis Pharma,” commented Vector Pharma FZCO Managing Partner, Patrick Jordan. “In Skytrofa, we have the opportunity for patients in our region to have access to an FDA- and European Commission-approved once-weekly treatment for children and adolescents with GHD, and Yorvipath as a European Commission-approved parathyroid hormone replacement therapy for adults with chronic hypoparathyroidism. Introducing TransCon technology-based therapeutics to the GCC will provide important tools for Endocrinologists and other Health Care Providers seeing these disorders.”